Millennium Management
CTMX icon

Millennium Management’s CytomX Therapeutics CTMX Stock Holding History

Millennium Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$387K – 6603
2021
Q1 		$387K Buy
+50,000
New +$396K ﹤0.01% 5033

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Millennium Management's CTMX Position: Q2 2026 in Review

Millennium Management reduced its CytomX Therapeutics (CTMX) stake by 54% in Q2 2026, selling an estimated $7.54M and leaving 1,685,830 shares worth $6.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2770.

Millennium Management first reported a position in CTMX in Q2 2016 and has held it in 40 quarters since. The position peaked at $17.7M in Q4 2017. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Millennium Management held 1,685,830 shares of CytomX Therapeutics worth $6.32M as of Q2 2026.
  • Millennium Management sold 1,974,360 CytomX Therapeutics shares in Q2 2026, an estimated $7.54M.
  • CytomX Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #2770 holding.
  • Millennium Management first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Millennium Management's CytomX Therapeutics position peaked at $17.7M in Q4 2017.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.